Comprehensive molecular analyses of urothelial bladder cancer (UBC) have defined distinct subtypes with potential therapeutic implications. In this study, we focused on micropapillary urothelial carcinoma (MPUC), an aggressive, histomorphologically defined rare variant. Apart from genetic alterations shared with conventional UBC alterations of the HER2 gene have been reported in higher frequencies. However, only small cohorts of MPUCs have been analyzed and the real impact is still unclear. We collected a cohort of 94 MPUCs and immunohistochemically tested HER2, basal (CD44, CK5, EGFR, p63) and luminal (CD24, FOXA1, GATA3, CK20) markers to allocate MPUC to a molecular subtype. Additionally, 
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Introduction
Urothelial bladder cancer (UBC) is the fifth most common malignancy worldwide in men and one of the most cost-consuming cancers as a result of financial expenses not only for therapy but also for life time follow-up examination. In the recent years and due to the lack of therapeutic advances and targeted therapies, comprehensive molecular characterization studies put a lot of effort and insight into the genomic landscape of UBC and provided several potential targets. Moreover, whole-genome mRNA expression profiling studies proposed distinct molecular categories of UBC similar to the breast cancer classification and defined different prognostic groups and appropriate therapeutic options [1] .
In this study, we focus on micropapillary urothelial carcinomas (MPUC), a rare subtype first reported by Amin et al. in 1994 , accounting for 0.7-6% of all UBC [2] . According to micropapillary carcinomas in other organs such as lung or breast, MPUC is histomorphologically characterized by several small-sized nests of tumor cells within lacunar spaces which may or may not have a central vascular core located [3] . Clinical and prognostic comparison between MPUC and conventional UBC showed a poorer prognosis for this distinct variant, probably due to a more aggressive behavior with frequent lymphatic invasion resulting in a higher rate of metastases [4, 5] .
Besides these differences in the clinical behavior, very limited data exist about the molecular background of this specific subtype. Interestingly, by testing the Human epidermal growth factor receptor 2 (HER2) gene amplification among UBC, mutated tumors presented more often with specific features such as micropapillary morphology [6] . HER2 is a receptor tyrosine-protein kinase and a member of the epidermal growth factor receptor family.
Activation of the receptor through dimerization and autophosphorylation initiates several signaling pathways including cell proliferation. In breast cancer, amplification or overexpression of HER2 are known to be responsible for the development of aggressive
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subtypes and the use of anti-HER2 antibodies combined with standard chemotherapy is well established and a prime example for an applied targeted therapy [7] . Concerning the possible association of MPUC and HER2 status, several studies identified a higher rate of HER2 amplification, mutations and/ or overexpression compared to the detected numbers in conventional urothelial tumors [8] [9] [10] [11] . However, due to the low incidence rates of MPUC the available reports are conducted in low sample sized cohorts (below 60 cases). Therefore, the real impact of a potential target among this histomorphological subgroup remains unclear.
The aim of our study was to collect the largest cohort of MPUC to date and to validate the expression, mutation and amplification status of the HER2 gene as a possible therapeutic strategy among MPUC tumors. Moreover, with regard to the recently identified molecular categories of UBC we used basal and luminal immunohistochemical markers to assign MPUC to a specific subgroup.
Materials and methods
Study cohort
In total, 94 archival formalin-fixed, paraffin-embedded MPUC of the urinary bladder were collected from several cooperation partners and from the files of the Institute of Pathology of the Friedrich-Alexander-University Erlangen-Nürnberg. Complete histomorphological reevaluation of at least one hematoxylin and eosin (H&E)-stained tumor slide according to the current WHO classification system was performed by two experienced uropathologists (A. H., S. B.) Reevaluation included assessment of the percentage of the micropapillary component in tumors with mixed morphology [3] . All cases presented the classical appearance of invasive micropapillary carcinomas and were included if at least 15% of the tumor showed clear micropapillary differentiation. 
Immunohistochemistry analysis
A tissue microarray (TMA) was constructed containing cores specifically punched from marked micropapillary regions of 94 MPUCs. Immunohistochemistry was performed on TMA slides including only the variant component using a Ventana Bench Mark Ultra automatic stainer. All antibodies used by this method are listed in 
HER2-Chromogenic in situ hybridization (CISH)
CISH analysis was performed on TMA slides using the SPEC HER2/CEN 17 Probe Kit (Zytovision) following the manufacturer's instructions. Scoring was performed according to the revised ASCO/CAP guidelines for HER2 amplification in breast cancer [12] .
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Microdissection and DNA isolation
According to marked H&E-stained sections of the evaluated tumors manual microdissection of the micropapillary component and DNA isolation was performed as described previously [14] . For DNA isolation the Maxwell 16 LEV Blood DNA Kit (Promega, Mannheim, Germany)
was used according to the manufacturer´s instructions and included only the variant component.
HER2 exon 4 and exon 8 mutation analysis
Exon 4 Biosystems ABI 3500 Genetic Analyzer (Applied Biosystems, Foster City, USA).
Statistical analysis
Kruskal-Wallis test was used to assess differences between the proportion of the MPUC components and were calculated using R, version 3.2.3. The heatmap.2 function of the gplots package within the R 3.2.3 statistical environment was used for non-hierarchical clustering based on immunoreactive scores of the evaluated markers.
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Results
HER2 protein expression and amplification
In total, 91/94 (96.8%) MPUC cases were evaluable for HER2 immunohistochemistry. Figure   2 shows representative images of the scoring. 36/91 (39.6%) tested MPUC demonstrated a HER2 score of 2+ and 3+ ( (Table 4) .
HER2 mutation analysis
The HER2 mutation status of exon 4 and 8 was analyzed in 90 available MPUC samples.
Sequencing data of both exons were available for 89/90 (98.7%) tumors (Table 5 ). The only alteration identified was a p.S310F mutation in 6/90 (6.7%) MPUCs located within exon 8
( Figure 3A ). In one case results were only available for exon 8 and presented wildtype HER2
sequence. Furthermore, we detected four MPUCs showing the minor T allele of the single nucleotide polymorphism (SNP) rs56114611 located within exon 4 ( Figure 3B ). Moreover, the combination of sequencing and CISH data revealed two HER2 p.S310F mutated MPUCs with concomitant HER2 amplification and three cases with a 2+/3+ HER2 scoring.
Immunohistochemical analysis of basal and luminal markers
90/94 MPUC with immunohistochemical results were included in the heat map analysis. Nonhierarchical clustering determined similarity of the used luminal and basal markers. Figure 4 ACCEPTED MANUSCRIPT
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illustrates the combination and expression levels of the different markers. (Table 6 ).
Discussion
MPUC is associated with aggressive behavior and poor survival most probably due to frequent lymphatic invasion and metastases [5, 15] . In comparison with MPUC of the upper urinary tract both malignancies present with similar aggressive characteristics [16] . Adverse outcomes despite aggressive platinum-based chemotherapy and limited response to Bacillus-Calmette-Guerin instillation therapy have been reported in MPUC, but little is known about alternative treatment strategies and most authors recommend early aggressive surgical treatment [5] . Recently, our own studies on MPUC showed worse outcome compared to conventional UBC after transurethral resection and radiochemotherapy [17] . In another study it has been shown that any amount of the MPUC variant is significant and should be reported [18] . Moreover, the biological scenario of the variant is largely unknown: a recent study reported that TERT mutations identified in UBC were also frequently observed among MPUC [19] . Improvement of our knowledge about this morphological variant and search for new therapy strategies are urgently needed.
Among breast cancer patients HER2 IHC analysis is used to identify patients suitable for
anti-HER2 targeted therapies [7] . In conventional UBC, HER2 overexpression frequencies have been reported ranging from 9.2 to 71% [20] [21] [22] . In the largest series of 1005 invasive UBC only 9.2% presented a positive (Score 2+ to 3+) HER2 staining [22] . and 3+) MPUC cases [10] . Another study detected an increased HER2 protein expression in 13/19 (68%) MPUC [11] . Moreover, an overexpression rate of 74% of 27 investigated MPUC tumors has been shown. However, more than half of these positive cases were scored 2+ according to the ASCO scoring system [24] . Recently, Behzatoglu et al. showed a 3+ staining in 34 of 60 MPUC [9] . In our own study, a 2+/3+ HER2 staining was found in 38.3%
of evaluable MPUC. The variability of IHC results among conventional or MPUC studies may be due to the cohort size as well as methodical differences. Despite standardized evaluation recommendations, assessment of IHC suffers from high interobserver variability depending on training of the pathologist [25] . In our department, HER2 immunohistochemical assay is validated in annual round-robin tests and protocols are certified according to ISO 17020.
Furthermore, evaluation of this study was performed by two experienced pathologists. Due to this high standardization and the large number of evaluated MPUC we summarize, that HER2 overexpression is particularly seen among MPUC.
Tschui et al. aimed to better characterize HER2 amplified UBC and observed micropapillary morphology as a hallmark of these mutated tumors [6] . During the last years, several studies reported HER2 amplifications in MPUC cohorts with variable frequencies of 15 to 42% [10, 26] . We found HER2 amplifications in 21 of 70 investigated MPUCs via CISH analysis. The high variability of reported frequencies may be due to the relatively small cohorts investigated in most studies. Additionally, the diversity may result from differences in methodology, i.e.
CISH or FISH, and analysis of TMA spots or whole tumor sections. Due to the high number of MPUC investigated in our study, the frequency of 30% HER2 amplifications, which lies in between the reported values, seems to be a realistic estimation of the actual percentage. In comparison to reported amplifications rates of 5.1-10% in unselected cohorts of UBC, HER2
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amplified tumors seem to be remarkably more frequent among the micropapillary variant [22, 27, 28] . Since our CISH analyses were performed on TMA slides, cases with heterogeneous distribution of HER2 amplifications may have been missed [22] . Summarized, almost one third of MPUC showed an HER2 amplification opening a promising therapy option for this rare subtype for example as a complementary therapeutic element in a neoadjuvant setting [29] .
Another point of interest is the absence of HER2 protein expression (score 0 or 1+) in 24% of there is no information whether these findings were validated by a second sequencing method [8] . Since we did not perform NGS based analysis we may have missed some mutations. However, a similar rate of 7% HER2 mutations was identified among the TCGA
cohort [31] . Our results suggest that somatic HER2 mutations do not seem to play a dominant role among MPUC patients.
Several comprehensive characterization studies based on mRNA expression profiling proposed molecular classification systems of UBC into prognostic significant distinct subtypes, whereby transfer of mRNA-based subtyping to immunohistochemical marker profiles is currently being discussed [1, 32] . A consensus paper summarized high CK5/14
and low levels of FOXA1/GATA3 as the characterizing markers of the basal type [33] . CD44, p63 and EGFR were previously identified and used as basal markers [1] . CK20 and CD24
are predominately represented among luminal tumors [1, 34] . In our study, by using a limited and selected immunohistochemical panel we detected a strong expression of the luminal markers CD24, FOXA1, GATA3 and CK20, whereas basal markers (CD44, CK5, EGFR, p63) were predominantly not expressed, assuming that MPUC represent the luminal subtype of UBC. Our results are in line with previous findings of the study by Guo et al. identifying the luminal character based on whole mRNA and immunohistochemical analyses of CD44, CK14, GATA3 and UPK2 in a cohort of 43 MPUC samples [35] . Additionally, HER2 amplification and overexpression were significantly more often identified in tumors with luminal characteristics and therefore operate in the context of the luminal pathway [29] . This co-occurrence of HER2 amplified and overexpressed samples among luminal tumors is in line with our findings among MPUC cases evolving through the luminal molecular pathway.
Conclusions
To the best of our knowledge, this is the largest cohort of MPUC to date being comprehensively evaluated for HER2 status by using immunohistochemistry, CISH and mutational analysis. Additionally, we were able to assign MPUC to the luminal molecular subtype using TMA based immunohistochemical analysis. Our findings and the size of our A C C E P T E D M A N U S C R I P T A C C E P T E D M A N U S C R I P T A C C E P T E D M A N U S C R I P T A C C E P T E D M A N U S C R I P T 
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